Safety and Efficacy Study of the Treatment of Kidney Infections With Short Course Levofloxacin

This study has been terminated.
Ortho-McNeil Pharmaceutical
Janssen-Ortho Inc., Canada
PriCara, Unit of Ortho-McNeil, Inc.
Information provided by:
University of Manitoba Identifier:
First received: October 12, 2005
Last updated: NA
Last verified: August 2005
History: No changes posted
The purpose of the study is to compare the safety and effectiveness of the antibiotic levofloxacin by administering a higher dose of levofloxacin using a shorter course of therapy to treat patients with infections of their kidney.

Condition Intervention Phase
Acute Uncomplicated Pyelonephritis
Drug: Levofloxacin
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by University of Manitoba:

Primary Outcome Measures:
  • Microbiological cure at the 10-14 day and 33-35 day followup

Secondary Outcome Measures:
  • Clinical outcome at each visit. Microbiologic outcomes at 24,48,and72 hrs, adverse antimicrobial effects, adverse events or antimicrobial resistance. Correlation between pharmacodynamic parameters, bacteriologic and clinical resolution will be analyzed.

Estimated Enrollment: 30
Study Start Date: September 2004
Estimated Study Completion Date: July 2005
Detailed Description:

The goal is to complete a pilot study of short course (5 days), high dose, levofloxacin treatment for women with acute uncomplicated pyelonephritis. Specific study objectives include:

  1. To assess the efficacy and tolerability of levofloxacin 750 mg once daily for treatment of acute uncomplicated pyelonephritis in 25 women.
  2. To describe the population pharmacokinetics of levofloxacin 750 mg once daily in treatment of young women with acute pyelonephritis.
  3. To identify urine proteins associated with the inflammatory response of acute pyelonephritis, and characterize the time course of resolution of these proteins following initiation of treatment.

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion criteria:

  • Recent onset (less than 7 days) of costovertebral angle pain or tenderness with or without fever, and with or without lower urinary tract symptoms (dysuria, frequency, urgency). Diabetic women without long term complications of diabetes (retinopathy, nephropathy, or neuropathy) may be enrolled.
  • Stable hemodynamic status and able to tolerate oral medication.
  • Pretherapy urine culture >107 cfu/L (>104 cfu/ml) of a uropathogen (E. coli, other Enterobacteriaceae, S. saprophyticus). Patients will be enrolled into the study prior to urine culture results being known. If pretherapy cultures are subsequently not positive (usually at 48 hours), subjects will be discontinued.
  • Pyuria (> 10 wbc/mm3 or > 10 X106 wbc/L by hemocytometer; > 6-10 wbc/hpf, or > 1+ LE (leukocyte esterase) dipstick).

Exclusion Criteria:

·Pregnancy, breastfeeding, fluoroquinolone allergy, and any underlying structural or functional genitourinary abnormality.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00239161

Canada, Manitoba
St. Boniface General Hospital
Winnipeg, Manitoba, Canada, R2H 2A6
Health Sciences Centre
Winnipeg, Manitoba, Canada, R3A 1R9
Misericordia Urgent Care
Winnipeg, Manitoba, Canada, R3C 1A2
University of Manitoba
Winnipeg, Manitoba, Canada, R3E 0W3
Sponsors and Collaborators
University of Manitoba
Ortho-McNeil Pharmaceutical
Janssen-Ortho Inc., Canada
PriCara, Unit of Ortho-McNeil, Inc.
Principal Investigator: Lindsay E Nicolle, MD, FRCPC University of Manitoba
Principal Investigator: Godfrey KM Harding, MD, FRCPC University of Manitoba
Principal Investigator: George G Zhanel, PhD, FCCP University of Manitoba
  More Information

No publications provided Identifier: NCT00239161     History of Changes
Other Study ID Numbers: CAPSS-353  LOF-UTI-2 
Study First Received: October 12, 2005
Last Updated: October 12, 2005
Health Authority: Canada: Health Canada

Keywords provided by University of Manitoba:

Additional relevant MeSH terms:
Kidney Diseases
Nephritis, Interstitial
Urologic Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Anti-Infective Agents, Urinary
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Renal Agents
Therapeutic Uses
Topoisomerase II Inhibitors
Topoisomerase Inhibitors processed this record on February 04, 2016